ALS is a debilitating paralytic disease characterized as the death of upper and lower motor neurons. Fortunately, ALS is relatively rare, with an incidence rate of 1.6 per 100,000 adults, resulting in about 30,000 cases in the United States at any one time.
A new artificial intelligence model could help design antibodies that better protect the body against viruses and disease. The AI model, known as ImmunoMatch, can predict and identify correct protein pairings within antibodies, potentially helping to strengthen the immune system. The research was conducted by a team from the University of Surrey and University College London and is published in Nature Methods.
BONADUZ, Switzerland, Dec. 16, 2025 /PRNewswire/ — Hamilton today announced the launch of GlucoSense, a breakthrough in bioprocess analytics that introduces the first reusable, in situ glucose sensor designed to deliver continuous, real-time measurements directly inside cell culture bioreactors.
Using new molecules that block an immune checkpoint, researchers showed they could stimulate a strong anti-tumor immune response.
BlueWind Medical announced today that the FDA granted 510(k) clearance for its enhanced Revi implantable tibial neuromodulation (iTNM) system.
Medivis announced today that it received FDA 510(k) clearance for its augmented reality (AR)-powered Cranial Navigation platform.
If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to attack its own nervous system. This mechanism can accelerate the progression of multiple sclerosis, as researchers at the University of Basel have shown in trials with mice. However, their results also open up opportunities for treatments that make use of the microbiome.
In a new nationwide study published in The Lancet that included Mayo Clinic, investigators found that patients with oropharyngeal cancer can live longer with fewer side effects if treated with proton beam radiation therapy.
The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial-based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic melanoma, was concluded with positive outcomes that encourage future vaccine developments and trials to test them in combination with immune checkpoint inhibitor therapies.
Respiratory viruses that have diverse strains and mutate rapidly, such as influenza and COVID-19, are difficult to block perfectly with vaccines alone. To solve this problem, KAIST’s research team has successfully developed an intranasal antiviral platform using AI technology to overcome the existing limitations of interferon-lambda treatments—namely, being weak against heat and disappearing quickly from the nasal mucosa.